| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diabetes Mellitus, Type 1 | 41 | 2021 | 529 | 5.660 |
Why?
|
| Pre-Eclampsia | 10 | 2021 | 202 | 4.900 |
Why?
|
| Lipoproteins, LDL | 41 | 2020 | 343 | 4.720 |
Why?
|
| Diabetic Retinopathy | 20 | 2022 | 110 | 3.950 |
Why?
|
| Pregnancy in Diabetics | 7 | 2020 | 70 | 3.300 |
Why?
|
| Metabolic Syndrome | 10 | 2021 | 191 | 2.670 |
Why?
|
| Lipoproteins | 15 | 2021 | 161 | 2.570 |
Why?
|
| Pericytes | 10 | 2016 | 81 | 2.520 |
Why?
|
| Fragaria | 7 | 2018 | 8 | 2.350 |
Why?
|
| Oxidative Stress | 15 | 2016 | 718 | 2.080 |
Why?
|
| Lipid Peroxidation | 9 | 2014 | 94 | 1.970 |
Why?
|
| Diabetic Angiopathies | 15 | 2019 | 203 | 1.870 |
Why?
|
| Diabetes Mellitus, Type 2 | 19 | 2022 | 1085 | 1.800 |
Why?
|
| Cholesterol, HDL | 9 | 2015 | 112 | 1.760 |
Why?
|
| Beverages | 7 | 2015 | 50 | 1.640 |
Why?
|
| Antioxidants | 9 | 2016 | 304 | 1.640 |
Why?
|
| Retina | 10 | 2021 | 252 | 1.610 |
Why?
|
| Pregnancy Trimester, First | 4 | 2020 | 43 | 1.520 |
Why?
|
| Retinal Vessels | 9 | 2022 | 74 | 1.480 |
Why?
|
| Fruit | 8 | 2019 | 86 | 1.400 |
Why?
|
| Glycation End Products, Advanced | 23 | 2016 | 125 | 1.280 |
Why?
|
| Diabetes, Gestational | 6 | 2022 | 81 | 1.270 |
Why?
|
| Hypolipidemic Agents | 4 | 2020 | 82 | 1.220 |
Why?
|
| Pregnancy | 18 | 2022 | 2334 | 1.200 |
Why?
|
| Diabetes Mellitus, Experimental | 6 | 2021 | 195 | 1.190 |
Why?
|
| Diabetes Mellitus | 13 | 2022 | 694 | 1.150 |
Why?
|
| Cardiovascular Diseases | 13 | 2021 | 940 | 1.130 |
Why?
|
| Capillaries | 7 | 2014 | 105 | 1.070 |
Why?
|
| Introduced Species | 3 | 2021 | 7 | 1.070 |
Why?
|
| Humans | 127 | 2022 | 68618 | 1.050 |
Why?
|
| Obesity | 8 | 2022 | 1076 | 1.020 |
Why?
|
| Cholesterol, LDL | 10 | 2014 | 161 | 0.950 |
Why?
|
| Apoptosis | 9 | 2018 | 1641 | 0.940 |
Why?
|
| Biomarkers | 22 | 2021 | 1593 | 0.930 |
Why?
|
| Phytotherapy | 4 | 2011 | 53 | 0.900 |
Why?
|
| Albuminuria | 7 | 2019 | 171 | 0.890 |
Why?
|
| Lipoproteins, HDL | 4 | 2015 | 113 | 0.870 |
Why?
|
| Adult | 59 | 2021 | 21403 | 0.870 |
Why?
|
| Female | 70 | 2022 | 38074 | 0.860 |
Why?
|
| Fenofibrate | 2 | 2020 | 23 | 0.840 |
Why?
|
| Dyslipidemias | 5 | 2015 | 98 | 0.840 |
Why?
|
| Blood-Retinal Barrier | 3 | 2021 | 15 | 0.810 |
Why?
|
| Serpins | 6 | 2019 | 205 | 0.810 |
Why?
|
| Diabetes Complications | 6 | 2019 | 249 | 0.810 |
Why?
|
| Nerve Growth Factors | 5 | 2019 | 75 | 0.790 |
Why?
|
| Tea | 2 | 2013 | 23 | 0.790 |
Why?
|
| Vaccinium macrocarpon | 2 | 2011 | 2 | 0.790 |
Why?
|
| Inflammation | 9 | 2021 | 1030 | 0.780 |
Why?
|
| Eye Proteins | 5 | 2019 | 160 | 0.750 |
Why?
|
| Cholesterol | 7 | 2015 | 331 | 0.740 |
Why?
|
| Autophagy | 3 | 2016 | 208 | 0.710 |
Why?
|
| Vitamin D-Binding Protein | 1 | 2020 | 58 | 0.700 |
Why?
|
| Haptoglobins | 1 | 2019 | 12 | 0.690 |
Why?
|
| Perciformes | 1 | 2019 | 8 | 0.680 |
Why?
|
| Insulin | 7 | 2021 | 619 | 0.670 |
Why?
|
| Indians, North American | 3 | 2015 | 64 | 0.660 |
Why?
|
| Retinal Pigment Epithelium | 1 | 2020 | 145 | 0.650 |
Why?
|
| Adipokines | 2 | 2022 | 20 | 0.640 |
Why?
|
| Endoplasmic Reticulum Stress | 3 | 2016 | 99 | 0.640 |
Why?
|
| Endothelium, Vascular | 6 | 2010 | 371 | 0.620 |
Why?
|
| Functional Food | 2 | 2017 | 3 | 0.620 |
Why?
|
| Blueberry Plants | 2 | 2021 | 5 | 0.600 |
Why?
|
| Vitamin D | 2 | 2020 | 516 | 0.590 |
Why?
|
| Diabetic Nephropathies | 6 | 2019 | 161 | 0.590 |
Why?
|
| Flavonoids | 3 | 2015 | 109 | 0.570 |
Why?
|
| Oxidation-Reduction | 17 | 2016 | 567 | 0.570 |
Why?
|
| Male | 62 | 2021 | 37321 | 0.570 |
Why?
|
| Young Adult | 17 | 2021 | 5717 | 0.570 |
Why?
|
| Ependymoglial Cells | 1 | 2016 | 7 | 0.550 |
Why?
|
| Cells, Cultured | 13 | 2020 | 2673 | 0.550 |
Why?
|
| Berberine | 1 | 2016 | 3 | 0.550 |
Why?
|
| Atherosclerosis | 3 | 2019 | 204 | 0.550 |
Why?
|
| Magnetic Resonance Spectroscopy | 8 | 2015 | 346 | 0.540 |
Why?
|
| Apolipoproteins | 4 | 2019 | 51 | 0.540 |
Why?
|
| C-Reactive Protein | 9 | 2014 | 180 | 0.540 |
Why?
|
| Antigen-Antibody Complex | 3 | 2014 | 175 | 0.530 |
Why?
|
| Cacao | 1 | 2015 | 11 | 0.520 |
Why?
|
| Carotid Intima-Media Thickness | 4 | 2018 | 54 | 0.510 |
Why?
|
| Glucose Intolerance | 1 | 2015 | 36 | 0.510 |
Why?
|
| Plant Extracts | 3 | 2013 | 122 | 0.510 |
Why?
|
| Prospective Studies | 12 | 2022 | 3705 | 0.500 |
Why?
|
| Kidney Diseases | 1 | 2017 | 307 | 0.490 |
Why?
|
| Carotenoids | 2 | 2013 | 45 | 0.490 |
Why?
|
| Zinc | 1 | 2015 | 73 | 0.490 |
Why?
|
| Longitudinal Studies | 7 | 2020 | 1054 | 0.490 |
Why?
|
| Placenta | 3 | 2021 | 101 | 0.490 |
Why?
|
| Middle Aged | 40 | 2021 | 21147 | 0.480 |
Why?
|
| Cell Survival | 6 | 2016 | 901 | 0.480 |
Why?
|
| Obesity, Abdominal | 1 | 2014 | 5 | 0.470 |
Why?
|
| Copper | 3 | 2015 | 149 | 0.470 |
Why?
|
| Food Handling | 1 | 2014 | 34 | 0.460 |
Why?
|
| Cohort Studies | 14 | 2020 | 2358 | 0.460 |
Why?
|
| Lipids | 6 | 2021 | 298 | 0.450 |
Why?
|
| Catechin | 2 | 2010 | 26 | 0.450 |
Why?
|
| Camellia sinensis | 2 | 2010 | 9 | 0.450 |
Why?
|
| Animals | 31 | 2022 | 20881 | 0.440 |
Why?
|
| Freeze Drying | 5 | 2017 | 18 | 0.430 |
Why?
|
| Apolipoprotein B-100 | 2 | 2011 | 7 | 0.410 |
Why?
|
| Hyperglycemia | 4 | 2019 | 158 | 0.410 |
Why?
|
| Pregnancy Complications | 1 | 2015 | 286 | 0.410 |
Why?
|
| Risk Factors | 17 | 2020 | 5731 | 0.400 |
Why?
|
| Sphingolipids | 3 | 2019 | 337 | 0.400 |
Why?
|
| Disease Models, Animal | 9 | 2021 | 2550 | 0.400 |
Why?
|
| Retinal Ganglion Cells | 1 | 2012 | 72 | 0.400 |
Why?
|
| Glycosylation | 11 | 2012 | 185 | 0.390 |
Why?
|
| Neuroglia | 1 | 2012 | 136 | 0.390 |
Why?
|
| Gene Expression Regulation | 4 | 2018 | 1293 | 0.390 |
Why?
|
| Awards and Prizes | 1 | 2011 | 27 | 0.390 |
Why?
|
| Insulin Resistance | 4 | 2019 | 241 | 0.380 |
Why?
|
| Glutathione | 1 | 2013 | 343 | 0.370 |
Why?
|
| Evidence-Based Medicine | 1 | 2014 | 438 | 0.370 |
Why?
|
| Body Mass Index | 7 | 2017 | 867 | 0.370 |
Why?
|
| Postprandial Period | 3 | 2020 | 21 | 0.350 |
Why?
|
| Blood Glucose | 10 | 2021 | 631 | 0.350 |
Why?
|
| Phenols | 1 | 2010 | 73 | 0.340 |
Why?
|
| Reactive Oxygen Species | 6 | 2016 | 499 | 0.340 |
Why?
|
| Resistin | 2 | 2020 | 9 | 0.330 |
Why?
|
| Organelle Biogenesis | 2 | 2020 | 34 | 0.330 |
Why?
|
| Interleukin-6 | 4 | 2018 | 330 | 0.320 |
Why?
|
| Leptin | 3 | 2022 | 80 | 0.320 |
Why?
|
| Mice | 15 | 2021 | 8474 | 0.310 |
Why?
|
| Randomized Controlled Trials as Topic | 5 | 2019 | 931 | 0.310 |
Why?
|
| Pregnancy Trimester, Second | 2 | 2020 | 58 | 0.310 |
Why?
|
| Lipopolysaccharides | 3 | 2019 | 455 | 0.310 |
Why?
|
| Skin | 10 | 2014 | 451 | 0.310 |
Why?
|
| Osteoarthritis, Knee | 2 | 2018 | 26 | 0.310 |
Why?
|
| Capillary Permeability | 3 | 2021 | 69 | 0.300 |
Why?
|
| Norway | 2 | 2019 | 18 | 0.300 |
Why?
|
| Body Weight | 1 | 2010 | 554 | 0.300 |
Why?
|
| Australia | 3 | 2019 | 235 | 0.300 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-3 | 1 | 2007 | 15 | 0.290 |
Why?
|
| Triglycerides | 7 | 2014 | 184 | 0.290 |
Why?
|
| Cross-Sectional Studies | 10 | 2018 | 2279 | 0.280 |
Why?
|
| Oklahoma | 4 | 2015 | 18 | 0.270 |
Why?
|
| Adiponectin | 2 | 2017 | 52 | 0.270 |
Why?
|
| Single-Blind Method | 3 | 2013 | 249 | 0.270 |
Why?
|
| Pheochromocytoma | 1 | 2005 | 22 | 0.260 |
Why?
|
| Adrenal Gland Neoplasms | 1 | 2005 | 26 | 0.260 |
Why?
|
| Double-Blind Method | 5 | 2020 | 1738 | 0.260 |
Why?
|
| Collagen | 13 | 2008 | 636 | 0.250 |
Why?
|
| Diet, High-Fat | 4 | 2020 | 81 | 0.250 |
Why?
|
| Mitochondria | 2 | 2020 | 643 | 0.250 |
Why?
|
| Lipoproteins, VLDL | 2 | 2004 | 32 | 0.250 |
Why?
|
| Adolescent | 18 | 2015 | 8912 | 0.250 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2018 | 626 | 0.240 |
Why?
|
| Esophageal Neoplasms | 1 | 2005 | 150 | 0.240 |
Why?
|
| Cytokines | 3 | 2019 | 866 | 0.230 |
Why?
|
| Trophoblasts | 2 | 2021 | 29 | 0.230 |
Why?
|
| Nitric Oxide Synthase Type II | 3 | 2016 | 201 | 0.230 |
Why?
|
| Malondialdehyde | 4 | 2011 | 43 | 0.230 |
Why?
|
| Mice, Inbred C57BL | 8 | 2019 | 2791 | 0.220 |
Why?
|
| In Situ Nick-End Labeling | 3 | 2018 | 160 | 0.220 |
Why?
|
| Hyperlipidemias | 1 | 2003 | 90 | 0.220 |
Why?
|
| Retinal Artery | 1 | 2022 | 10 | 0.210 |
Why?
|
| Gene Expression | 1 | 2005 | 770 | 0.210 |
Why?
|
| Florida | 2 | 2021 | 221 | 0.210 |
Why?
|
| Wounds and Injuries | 3 | 2019 | 334 | 0.210 |
Why?
|
| Lysine | 11 | 2001 | 96 | 0.210 |
Why?
|
| Hypercholesterolemia | 1 | 2003 | 86 | 0.210 |
Why?
|
| Glomerular Filtration Rate | 3 | 2019 | 274 | 0.210 |
Why?
|
| Alcohol Oxidoreductases | 1 | 2002 | 31 | 0.210 |
Why?
|
| Protein Transport | 3 | 2014 | 280 | 0.200 |
Why?
|
| Risk | 2 | 2015 | 563 | 0.200 |
Why?
|
| MAP Kinase Signaling System | 2 | 2016 | 247 | 0.200 |
Why?
|
| Lipid Peroxides | 2 | 2018 | 19 | 0.200 |
Why?
|
| Cross-Over Studies | 3 | 2019 | 260 | 0.200 |
Why?
|
| Predatory Behavior | 1 | 2021 | 10 | 0.200 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 2 | 2019 | 87 | 0.200 |
Why?
|
| Endothelial Cells | 2 | 2018 | 384 | 0.200 |
Why?
|
| Prenatal Nutritional Physiological Phenomena | 1 | 2021 | 4 | 0.190 |
Why?
|
| Aged | 16 | 2018 | 14862 | 0.190 |
Why?
|
| Uric Acid | 1 | 2021 | 37 | 0.190 |
Why?
|
| Dietary Fiber | 1 | 2021 | 37 | 0.190 |
Why?
|
| Piperidines | 1 | 2021 | 123 | 0.190 |
Why?
|
| Ecosystem | 1 | 2021 | 54 | 0.190 |
Why?
|
| Fluorescein-5-isothiocyanate | 1 | 2020 | 10 | 0.190 |
Why?
|
| Dextrans | 1 | 2020 | 33 | 0.190 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 1 | 2021 | 24 | 0.190 |
Why?
|
| DNA, Mitochondrial | 2 | 2020 | 84 | 0.190 |
Why?
|
| Chocolate | 1 | 2020 | 2 | 0.180 |
Why?
|
| Phenotype | 3 | 2019 | 947 | 0.180 |
Why?
|
| Receptors, LDL | 4 | 2019 | 72 | 0.180 |
Why?
|
| Pyrimidines | 1 | 2021 | 178 | 0.180 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 2 | 2010 | 45 | 0.180 |
Why?
|
| Diet | 2 | 2021 | 514 | 0.180 |
Why?
|
| Anesthesia | 1 | 2021 | 120 | 0.180 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2005 | 629 | 0.180 |
Why?
|
| Endoplasmic Reticulum | 2 | 2012 | 148 | 0.180 |
Why?
|
| Guanidines | 1 | 2000 | 32 | 0.180 |
Why?
|
| Blood Pressure | 3 | 2018 | 1451 | 0.180 |
Why?
|
| Nitric Oxide | 4 | 2011 | 382 | 0.180 |
Why?
|
| United States | 5 | 2019 | 7367 | 0.180 |
Why?
|
| Particle Size | 4 | 2010 | 201 | 0.180 |
Why?
|
| Amitriptyline | 1 | 2019 | 11 | 0.180 |
Why?
|
| Dietary Fats | 1 | 2020 | 103 | 0.180 |
Why?
|
| Creatinine | 3 | 2017 | 243 | 0.180 |
Why?
|
| Electric Impedance | 1 | 2020 | 131 | 0.180 |
Why?
|
| Gulf of Mexico | 1 | 2019 | 5 | 0.170 |
Why?
|
| Caribbean Region | 1 | 2019 | 10 | 0.170 |
Why?
|
| Atlantic Ocean | 1 | 2019 | 22 | 0.170 |
Why?
|
| Time Factors | 5 | 2020 | 4655 | 0.170 |
Why?
|
| Vitamin E | 1 | 1999 | 55 | 0.170 |
Why?
|
| Cattle | 6 | 2010 | 475 | 0.170 |
Why?
|
| Rubus | 1 | 2019 | 1 | 0.170 |
Why?
|
| Real-Time Polymerase Chain Reaction | 2 | 2018 | 209 | 0.170 |
Why?
|
| Arteriosclerosis | 3 | 2003 | 137 | 0.170 |
Why?
|
| Kallikreins | 1 | 2020 | 323 | 0.170 |
Why?
|
| Methionine | 3 | 2008 | 36 | 0.160 |
Why?
|
| Glucose | 4 | 1997 | 307 | 0.160 |
Why?
|
| Pregnancy Outcome | 1 | 2019 | 157 | 0.160 |
Why?
|
| Vitreous Body | 1 | 2018 | 26 | 0.160 |
Why?
|
| Analysis of Variance | 3 | 2016 | 1040 | 0.160 |
Why?
|
| Palmitates | 1 | 2018 | 20 | 0.160 |
Why?
|
| Platelet Count | 2 | 2009 | 100 | 0.160 |
Why?
|
| Lipid Metabolism | 3 | 2013 | 186 | 0.160 |
Why?
|
| Palmitic Acid | 1 | 2018 | 51 | 0.160 |
Why?
|
| Prevalence | 4 | 2015 | 1619 | 0.160 |
Why?
|
| Blotting, Western | 2 | 2012 | 954 | 0.150 |
Why?
|
| Infant, Newborn | 8 | 2022 | 2455 | 0.150 |
Why?
|
| Hepatitis A Virus Cellular Receptor 1 | 1 | 2017 | 9 | 0.150 |
Why?
|
| Sphingomyelin Phosphodiesterase | 1 | 2019 | 183 | 0.150 |
Why?
|
| Lipocalin-2 | 1 | 2017 | 19 | 0.150 |
Why?
|
| Retinol-Binding Proteins, Plasma | 1 | 2017 | 12 | 0.150 |
Why?
|
| Fatty Acid-Binding Proteins | 1 | 2017 | 30 | 0.150 |
Why?
|
| Receptors, Scavenger | 2 | 2014 | 13 | 0.150 |
Why?
|
| Trauma Centers | 1 | 2019 | 197 | 0.150 |
Why?
|
| Vitamin D Deficiency | 1 | 2020 | 292 | 0.150 |
Why?
|
| Arthralgia | 1 | 2017 | 30 | 0.150 |
Why?
|
| Fatty Acids | 1 | 2018 | 222 | 0.150 |
Why?
|
| Fluorescence | 2 | 2014 | 104 | 0.140 |
Why?
|
| Thrombosis | 2 | 2016 | 218 | 0.140 |
Why?
|
| Beclin-1 | 1 | 2016 | 11 | 0.140 |
Why?
|
| Amino Acid Chloromethyl Ketones | 1 | 2016 | 24 | 0.140 |
Why?
|
| Hepatocytes | 1 | 2018 | 205 | 0.140 |
Why?
|
| Enzyme Inhibitors | 1 | 2019 | 659 | 0.140 |
Why?
|
| Transcription Factor CHOP | 1 | 2016 | 28 | 0.140 |
Why?
|
| Adenine | 1 | 2016 | 46 | 0.140 |
Why?
|
| Intracellular Space | 2 | 2014 | 42 | 0.140 |
Why?
|
| Critical Care | 1 | 2019 | 263 | 0.140 |
Why?
|
| Interleukin-8 | 1 | 2016 | 71 | 0.140 |
Why?
|
| Basilar Artery | 1 | 2016 | 38 | 0.130 |
Why?
|
| Electroretinography | 1 | 2016 | 122 | 0.130 |
Why?
|
| Aldehydes | 3 | 2010 | 34 | 0.130 |
Why?
|
| Breakfast | 1 | 2015 | 2 | 0.130 |
Why?
|
| Immunohistochemistry | 2 | 2016 | 1174 | 0.130 |
Why?
|
| Laser Coagulation | 1 | 2015 | 8 | 0.130 |
Why?
|
| Mice, Knockout | 4 | 2019 | 1692 | 0.130 |
Why?
|
| Tyrosine | 2 | 2011 | 196 | 0.130 |
Why?
|
| Vascular Stiffness | 1 | 2015 | 31 | 0.130 |
Why?
|
| Child of Impaired Parents | 1 | 2015 | 18 | 0.130 |
Why?
|
| Glucose Tolerance Test | 1 | 2015 | 75 | 0.130 |
Why?
|
| Biological Assay | 1 | 2016 | 88 | 0.130 |
Why?
|
| Fetal Blood | 3 | 2022 | 131 | 0.130 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2015 | 64 | 0.130 |
Why?
|
| Protein Processing, Post-Translational | 2 | 2008 | 284 | 0.120 |
Why?
|
| Apolipoproteins C | 2 | 2005 | 15 | 0.120 |
Why?
|
| Rest | 1 | 2015 | 78 | 0.120 |
Why?
|
| Receptors, Lipoprotein | 1 | 1994 | 11 | 0.120 |
Why?
|
| Spectrometry, Fluorescence | 3 | 2013 | 112 | 0.120 |
Why?
|
| Prenatal Diagnosis | 1 | 2015 | 73 | 0.120 |
Why?
|
| Early Diagnosis | 1 | 2015 | 122 | 0.120 |
Why?
|
| Child Development | 1 | 2015 | 102 | 0.120 |
Why?
|
| Arylamine N-Acetyltransferase | 1 | 2014 | 11 | 0.120 |
Why?
|
| Homocysteine | 1 | 2014 | 28 | 0.120 |
Why?
|
| Hypoglycemic Agents | 3 | 2013 | 362 | 0.120 |
Why?
|
| Birth Weight | 1 | 2015 | 186 | 0.120 |
Why?
|
| Prognosis | 1 | 2019 | 2093 | 0.120 |
Why?
|
| Case-Control Studies | 3 | 2020 | 1553 | 0.120 |
Why?
|
| Phytochemicals | 1 | 2014 | 6 | 0.120 |
Why?
|
| Rats | 8 | 2022 | 5300 | 0.120 |
Why?
|
| Proteins | 4 | 2001 | 474 | 0.110 |
Why?
|
| Immunoglobulin G | 2 | 2014 | 481 | 0.110 |
Why?
|
| Adipose Tissue | 1 | 2015 | 221 | 0.110 |
Why?
|
| Wnt Signaling Pathway | 1 | 2014 | 57 | 0.110 |
Why?
|
| APOBEC-1 Deaminase | 2 | 2003 | 6 | 0.110 |
Why?
|
| Disease Progression | 5 | 2019 | 1038 | 0.110 |
Why?
|
| Polymorphism, Genetic | 2 | 2005 | 301 | 0.110 |
Why?
|
| Cytidine Deaminase | 2 | 2003 | 17 | 0.110 |
Why?
|
| Immunoblotting | 2 | 2018 | 254 | 0.110 |
Why?
|
| Tocopherols | 1 | 2013 | 7 | 0.110 |
Why?
|
| Interleukin 1 Receptor Antagonist Protein | 1 | 2013 | 17 | 0.110 |
Why?
|
| Chemokine CXCL10 | 1 | 2013 | 21 | 0.110 |
Why?
|
| Glutathione Peroxidase | 1 | 2013 | 39 | 0.110 |
Why?
|
| Energy Metabolism | 1 | 2015 | 222 | 0.110 |
Why?
|
| Receptors, IgG | 1 | 2014 | 94 | 0.110 |
Why?
|
| E-Selectin | 1 | 2013 | 44 | 0.110 |
Why?
|
| Trace Elements | 1 | 2013 | 23 | 0.110 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2021 | 331 | 0.110 |
Why?
|
| Liver | 1 | 2018 | 1118 | 0.110 |
Why?
|
| Catalase | 1 | 2013 | 85 | 0.110 |
Why?
|
| Aging | 7 | 2013 | 911 | 0.110 |
Why?
|
| PPAR alpha | 1 | 2012 | 31 | 0.110 |
Why?
|
| Maillard Reaction | 5 | 1997 | 7 | 0.110 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 2 | 2005 | 58 | 0.100 |
Why?
|
| Muscle, Smooth, Vascular | 1 | 1994 | 317 | 0.100 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2014 | 786 | 0.100 |
Why?
|
| Intramolecular Oxidoreductases | 1 | 2011 | 10 | 0.100 |
Why?
|
| Computed Tomography Angiography | 1 | 2016 | 424 | 0.100 |
Why?
|
| Wound Healing | 1 | 2014 | 260 | 0.100 |
Why?
|
| Up-Regulation | 2 | 2018 | 682 | 0.100 |
Why?
|
| Tennessee | 1 | 2011 | 11 | 0.100 |
Why?
|
| Fibric Acids | 1 | 2011 | 12 | 0.100 |
Why?
|
| Niacin | 1 | 2011 | 12 | 0.100 |
Why?
|
| Cytochrome P-450 Enzyme System | 1 | 2011 | 62 | 0.100 |
Why?
|
| Superoxide Dismutase | 2 | 2011 | 149 | 0.100 |
Why?
|
| beta Carotene | 1 | 2011 | 16 | 0.100 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2014 | 627 | 0.100 |
Why?
|
| History, 21st Century | 1 | 2011 | 127 | 0.090 |
Why?
|
| Clusterin | 1 | 2010 | 13 | 0.090 |
Why?
|
| Research Personnel | 1 | 2011 | 83 | 0.090 |
Why?
|
| Macrophages | 2 | 2019 | 647 | 0.090 |
Why?
|
| Nitric Oxide Synthase Type III | 2 | 2009 | 102 | 0.090 |
Why?
|
| Food, Preserved | 1 | 2010 | 2 | 0.090 |
Why?
|
| History, 20th Century | 1 | 2011 | 248 | 0.090 |
Why?
|
| Veterans | 2 | 2019 | 904 | 0.090 |
Why?
|
| Vitamin A | 1 | 2011 | 111 | 0.090 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 2010 | 52 | 0.090 |
Why?
|
| Anthocyanins | 1 | 2010 | 5 | 0.090 |
Why?
|
| Schools, Medical | 1 | 2011 | 157 | 0.090 |
Why?
|
| Dietary Supplements | 1 | 2013 | 332 | 0.090 |
Why?
|
| Community Pharmacy Services | 1 | 2010 | 11 | 0.090 |
Why?
|
| Membrane Proteins | 1 | 1994 | 617 | 0.090 |
Why?
|
| Biological Availability | 1 | 2010 | 79 | 0.090 |
Why?
|
| Interleukin-1beta | 1 | 2010 | 88 | 0.090 |
Why?
|
| AMP-Activated Protein Kinases | 1 | 2010 | 48 | 0.090 |
Why?
|
| Tunica Media | 2 | 2008 | 33 | 0.090 |
Why?
|
| Retinal Neovascularization | 1 | 2009 | 7 | 0.090 |
Why?
|
| Polyphenols | 1 | 2010 | 34 | 0.090 |
Why?
|
| Tunica Intima | 2 | 2008 | 59 | 0.090 |
Why?
|
| Wnt Proteins | 1 | 2009 | 57 | 0.090 |
Why?
|
| Retinopathy of Prematurity | 1 | 2009 | 34 | 0.090 |
Why?
|
| Hypertension | 3 | 2014 | 1535 | 0.080 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 3 | 1 | 2009 | 46 | 0.080 |
Why?
|
| Gas Chromatography-Mass Spectrometry | 5 | 2001 | 59 | 0.080 |
Why?
|
| Cell Count | 2 | 2000 | 248 | 0.080 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2011 | 212 | 0.080 |
Why?
|
| Infant | 5 | 2022 | 2891 | 0.080 |
Why?
|
| Follow-Up Studies | 4 | 2019 | 3259 | 0.080 |
Why?
|
| Vitamins | 1 | 2010 | 134 | 0.080 |
Why?
|
| Butadienes | 1 | 2009 | 26 | 0.080 |
Why?
|
| Anthracenes | 1 | 2009 | 26 | 0.080 |
Why?
|
| Students, Pharmacy | 1 | 2010 | 79 | 0.080 |
Why?
|
| Regression Analysis | 4 | 2018 | 737 | 0.080 |
Why?
|
| Societies, Medical | 1 | 2011 | 403 | 0.080 |
Why?
|
| Nitriles | 1 | 2009 | 68 | 0.080 |
Why?
|
| Cardiac Myosins | 1 | 2008 | 12 | 0.080 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 1 | 2009 | 140 | 0.080 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2009 | 134 | 0.080 |
Why?
|
| Caspase 7 | 1 | 2008 | 6 | 0.080 |
Why?
|
| Myocarditis | 1 | 2008 | 49 | 0.080 |
Why?
|
| Phospholipids | 2 | 1999 | 108 | 0.080 |
Why?
|
| Aged, 80 and over | 7 | 2018 | 4848 | 0.080 |
Why?
|
| Fluorescent Antibody Technique, Indirect | 1 | 2008 | 95 | 0.080 |
Why?
|
| Imidazoles | 1 | 2009 | 175 | 0.080 |
Why?
|
| Peroxynitrous Acid | 1 | 2008 | 55 | 0.080 |
Why?
|
| Apolipoprotein A-I | 1 | 2008 | 29 | 0.080 |
Why?
|
| Renal Dialysis | 1 | 2009 | 174 | 0.080 |
Why?
|
| Vascular Endothelial Growth Factor A | 2 | 2022 | 219 | 0.080 |
Why?
|
| Pelvic Bones | 1 | 2007 | 7 | 0.080 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2009 | 175 | 0.080 |
Why?
|
| Chemokine CCL2 | 1 | 2008 | 101 | 0.080 |
Why?
|
| Stem Cells | 1 | 2009 | 248 | 0.080 |
Why?
|
| Rats, Sprague-Dawley | 5 | 2021 | 2083 | 0.080 |
Why?
|
| Phosphorylation | 2 | 2009 | 1200 | 0.080 |
Why?
|
| Caspase 3 | 1 | 2008 | 233 | 0.070 |
Why?
|
| Cell Culture Techniques | 1 | 2008 | 189 | 0.070 |
Why?
|
| Patient Compliance | 1 | 2010 | 402 | 0.070 |
Why?
|
| Calpain | 1 | 2008 | 205 | 0.070 |
Why?
|
| Cell Nucleus | 1 | 2008 | 305 | 0.070 |
Why?
|
| Blood Platelets | 1 | 2008 | 284 | 0.070 |
Why?
|
| Patient Education as Topic | 1 | 2010 | 425 | 0.070 |
Why?
|
| Pyridines | 1 | 2009 | 261 | 0.070 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2005 | 710 | 0.070 |
Why?
|
| Cardiomyopathies | 1 | 2008 | 167 | 0.070 |
Why?
|
| Cell Movement | 1 | 2009 | 630 | 0.070 |
Why?
|
| Fractures, Bone | 1 | 2007 | 132 | 0.070 |
Why?
|
| Citric Acid Cycle | 1 | 2006 | 15 | 0.070 |
Why?
|
| Polymerase Chain Reaction | 1 | 2007 | 492 | 0.070 |
Why?
|
| NF-kappa B | 1 | 2008 | 432 | 0.070 |
Why?
|
| Kidney Failure, Chronic | 1 | 2009 | 365 | 0.070 |
Why?
|
| Autoantibodies | 1 | 2008 | 434 | 0.070 |
Why?
|
| Cysteine | 1 | 2006 | 112 | 0.070 |
Why?
|
| Predictive Value of Tests | 3 | 2014 | 1465 | 0.070 |
Why?
|
| Carotid Artery, Internal | 1 | 2006 | 85 | 0.060 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2005 | 76 | 0.060 |
Why?
|
| DNA Fragmentation | 1 | 2005 | 85 | 0.060 |
Why?
|
| Sphingomyelins | 2 | 2018 | 106 | 0.060 |
Why?
|
| New South Wales | 2 | 2019 | 10 | 0.060 |
Why?
|
| Down-Regulation | 2 | 2019 | 447 | 0.060 |
Why?
|
| Kidney | 2 | 2014 | 945 | 0.060 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2005 | 320 | 0.060 |
Why?
|
| Radiography | 1 | 2005 | 572 | 0.060 |
Why?
|
| Signal Transduction | 2 | 2009 | 2689 | 0.060 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2018 | 507 | 0.060 |
Why?
|
| Child, Preschool | 4 | 2019 | 3187 | 0.060 |
Why?
|
| Basement Membrane | 1 | 2003 | 48 | 0.050 |
Why?
|
| Streptozocin | 1 | 2003 | 34 | 0.050 |
Why?
|
| Gene Expression Profiling | 1 | 2005 | 498 | 0.050 |
Why?
|
| Glycoproteins | 1 | 2004 | 238 | 0.050 |
Why?
|
| TRPV Cation Channels | 1 | 2022 | 17 | 0.050 |
Why?
|
| Microscopy, Electron | 1 | 2003 | 351 | 0.050 |
Why?
|
| Arterioles | 1 | 2022 | 40 | 0.050 |
Why?
|
| C-Peptide | 1 | 2022 | 23 | 0.050 |
Why?
|
| Kidney Tubules | 1 | 2003 | 80 | 0.050 |
Why?
|
| Neoplasms | 1 | 2014 | 1667 | 0.050 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2005 | 296 | 0.050 |
Why?
|
| Scavenger Receptors, Class B | 2 | 2009 | 18 | 0.050 |
Why?
|
| Genotype | 3 | 2014 | 786 | 0.050 |
Why?
|
| Diagnosis, Differential | 1 | 2005 | 1140 | 0.050 |
Why?
|
| Medetomidine | 1 | 2021 | 6 | 0.050 |
Why?
|
| Xylazine | 1 | 2021 | 5 | 0.050 |
Why?
|
| Adrenergic Agents | 1 | 2021 | 14 | 0.050 |
Why?
|
| Pentobarbital | 1 | 2021 | 19 | 0.050 |
Why?
|
| Endoscopy | 1 | 2005 | 464 | 0.050 |
Why?
|
| Deglutition Disorders | 1 | 2005 | 297 | 0.050 |
Why?
|
| Nuclear Magnetic Resonance, Biomolecular | 2 | 2013 | 85 | 0.050 |
Why?
|
| Adiposity | 1 | 2022 | 88 | 0.050 |
Why?
|
| Aquatic Organisms | 1 | 2021 | 9 | 0.050 |
Why?
|
| Child | 5 | 2019 | 6405 | 0.050 |
Why?
|
| Climate Change | 1 | 2021 | 17 | 0.050 |
Why?
|
| Bone Density | 1 | 2022 | 159 | 0.050 |
Why?
|
| Fresh Water | 1 | 2021 | 43 | 0.050 |
Why?
|
| Sex Characteristics | 3 | 2010 | 295 | 0.050 |
Why?
|
| Ceramides | 2 | 2018 | 578 | 0.050 |
Why?
|
| Homeostasis | 1 | 2022 | 291 | 0.050 |
Why?
|
| Enzyme Activation | 3 | 2010 | 791 | 0.050 |
Why?
|
| Glomerular Mesangium | 1 | 2000 | 53 | 0.050 |
Why?
|
| Plant Preparations | 1 | 2020 | 18 | 0.050 |
Why?
|
| Cell Proliferation | 2 | 2018 | 1174 | 0.040 |
Why?
|
| Microcirculation | 2 | 2014 | 77 | 0.040 |
Why?
|
| Benzylidene Compounds | 1 | 2019 | 16 | 0.040 |
Why?
|
| Mitochondrial Dynamics | 1 | 2019 | 17 | 0.040 |
Why?
|
| Maternal Exposure | 1 | 2020 | 75 | 0.040 |
Why?
|
| Aniline Compounds | 1 | 2019 | 52 | 0.040 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2020 | 124 | 0.040 |
Why?
|
| Sorbitol | 1 | 1999 | 3 | 0.040 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2000 | 250 | 0.040 |
Why?
|
| Nitrites | 1 | 1999 | 53 | 0.040 |
Why?
|
| Transcription, Genetic | 2 | 2014 | 562 | 0.040 |
Why?
|
| Protein Kinases | 1 | 2019 | 122 | 0.040 |
Why?
|
| Serine | 1 | 1999 | 99 | 0.040 |
Why?
|
| Peer Review, Health Care | 1 | 2019 | 4 | 0.040 |
Why?
|
| Proteomics | 2 | 2012 | 246 | 0.040 |
Why?
|
| Mice, Transgenic | 2 | 2014 | 1033 | 0.040 |
Why?
|
| Adenosine Triphosphate | 1 | 2020 | 314 | 0.040 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 2020 | 154 | 0.040 |
Why?
|
| Stress, Physiological | 1 | 2020 | 215 | 0.040 |
Why?
|
| Lactosylceramides | 1 | 2018 | 27 | 0.040 |
Why?
|
| Drug Combinations | 1 | 1999 | 304 | 0.040 |
Why?
|
| Cadaver | 1 | 2018 | 136 | 0.040 |
Why?
|
| Medical Records | 1 | 2019 | 121 | 0.040 |
Why?
|
| Microvessels | 1 | 2018 | 43 | 0.040 |
Why?
|
| Injury Severity Score | 1 | 2019 | 204 | 0.040 |
Why?
|
| Endothelin-1 | 1 | 1999 | 122 | 0.040 |
Why?
|
| Drug Synergism | 1 | 2018 | 260 | 0.040 |
Why?
|
| Antigens, CD | 1 | 2018 | 230 | 0.040 |
Why?
|
| Fruit and Vegetable Juices | 1 | 2017 | 2 | 0.040 |
Why?
|
| Clinical Trials as Topic | 2 | 2013 | 848 | 0.040 |
Why?
|
| Triage | 1 | 2019 | 109 | 0.040 |
Why?
|
| Lipoprotein(a) | 1 | 1997 | 9 | 0.040 |
Why?
|
| Ethanolamines | 1 | 1997 | 33 | 0.040 |
Why?
|
| Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha | 1 | 2017 | 51 | 0.040 |
Why?
|
| Sensitivity and Specificity | 2 | 2014 | 1753 | 0.040 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2019 | 161 | 0.040 |
Why?
|
| Comorbidity | 2 | 2014 | 1426 | 0.040 |
Why?
|
| Severity of Illness Index | 2 | 2017 | 1851 | 0.040 |
Why?
|
| Knee Joint | 1 | 2017 | 115 | 0.040 |
Why?
|
| Incidence | 2 | 2014 | 1603 | 0.040 |
Why?
|
| Mitochondrial Proteins | 1 | 2017 | 113 | 0.030 |
Why?
|
| Escherichia coli | 1 | 2018 | 368 | 0.030 |
Why?
|
| Death, Sudden | 1 | 2016 | 24 | 0.030 |
Why?
|
| Pain Measurement | 1 | 2017 | 328 | 0.030 |
Why?
|
| Aorta | 2 | 2010 | 316 | 0.030 |
Why?
|
| Osmolar Concentration | 2 | 2010 | 134 | 0.030 |
Why?
|
| Vertebrobasilar Insufficiency | 1 | 2016 | 21 | 0.030 |
Why?
|
| Amino Acid Sequence | 2 | 2008 | 1083 | 0.030 |
Why?
|
| Survival Rate | 1 | 2019 | 1056 | 0.030 |
Why?
|
| Inflammation Mediators | 1 | 2017 | 244 | 0.030 |
Why?
|
| Ranibizumab | 1 | 2015 | 3 | 0.030 |
Why?
|
| Intravitreal Injections | 1 | 2015 | 16 | 0.030 |
Why?
|
| Cerebral Angiography | 1 | 2016 | 151 | 0.030 |
Why?
|
| Cell Line | 1 | 2019 | 1752 | 0.030 |
Why?
|
| Smoking | 2 | 2014 | 1452 | 0.030 |
Why?
|
| Bevacizumab | 1 | 2015 | 34 | 0.030 |
Why?
|
| Serum Albumin | 2 | 2006 | 104 | 0.030 |
Why?
|
| Apolipoprotein C-III | 2 | 2005 | 12 | 0.030 |
Why?
|
| Ketoses | 1 | 1994 | 1 | 0.030 |
Why?
|
| Thiobarbituric Acid Reactive Substances | 1 | 1994 | 17 | 0.030 |
Why?
|
| Body Composition | 1 | 2015 | 119 | 0.030 |
Why?
|
| Hyperhomocysteinemia | 1 | 2014 | 15 | 0.030 |
Why?
|
| Receptors, Immunologic | 1 | 1994 | 72 | 0.030 |
Why?
|
| Acetylation | 1 | 2014 | 94 | 0.030 |
Why?
|
| Glycogen Synthase Kinase 3 beta | 1 | 2014 | 57 | 0.030 |
Why?
|
| Lithium | 1 | 2014 | 76 | 0.030 |
Why?
|
| Glycogen Synthase Kinase 3 | 1 | 2014 | 64 | 0.030 |
Why?
|
| Sulfonylurea Compounds | 1 | 2013 | 17 | 0.030 |
Why?
|
| Genes, Reporter | 1 | 2014 | 191 | 0.030 |
Why?
|
| Hair Follicle | 1 | 2014 | 37 | 0.030 |
Why?
|
| Forearm | 1 | 2013 | 25 | 0.030 |
Why?
|
| Sex Factors | 1 | 2017 | 1266 | 0.030 |
Why?
|
| Age Factors | 2 | 2014 | 1864 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2017 | 1342 | 0.030 |
Why?
|
| DNA-Binding Proteins | 1 | 2017 | 700 | 0.030 |
Why?
|
| Metformin | 1 | 2013 | 63 | 0.030 |
Why?
|
| Thiazolidinediones | 1 | 2013 | 77 | 0.030 |
Why?
|
| Genome-Wide Association Study | 1 | 2014 | 240 | 0.030 |
Why?
|
| Transcription Factors | 1 | 2017 | 753 | 0.030 |
Why?
|
| Models, Biological | 1 | 1997 | 981 | 0.030 |
Why?
|
| Rats, Inbred BN | 1 | 2012 | 51 | 0.030 |
Why?
|
| Neovascularization, Pathologic | 1 | 2014 | 183 | 0.030 |
Why?
|
| Leukocytes | 1 | 2012 | 99 | 0.030 |
Why?
|
| Computer Simulation | 1 | 2016 | 706 | 0.030 |
Why?
|
| Metabolomics | 1 | 2012 | 28 | 0.030 |
Why?
|
| NG-Nitroarginine Methyl Ester | 1 | 2011 | 23 | 0.030 |
Why?
|
| Cyclic N-Oxides | 1 | 2011 | 17 | 0.030 |
Why?
|
| Spin Labels | 1 | 2011 | 27 | 0.020 |
Why?
|
| Tight Junctions | 1 | 2011 | 25 | 0.020 |
Why?
|
| United States Department of Veterans Affairs | 1 | 2013 | 307 | 0.020 |
Why?
|
| Cell Adhesion | 1 | 2012 | 324 | 0.020 |
Why?
|
| Receptors, Thromboxane | 1 | 2011 | 122 | 0.020 |
Why?
|
| Hydroxylysine | 1 | 1991 | 1 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2013 | 880 | 0.020 |
Why?
|
| Cyclooxygenase 2 | 1 | 2011 | 160 | 0.020 |
Why?
|
| Calcium | 2 | 2008 | 929 | 0.020 |
Why?
|
| Indicator Dilution Techniques | 1 | 2010 | 8 | 0.020 |
Why?
|
| Genomics | 1 | 2012 | 168 | 0.020 |
Why?
|
| Washington | 1 | 2010 | 27 | 0.020 |
Why?
|
| Arginine | 3 | 1997 | 102 | 0.020 |
Why?
|
| Chromatography, Liquid | 1 | 2010 | 120 | 0.020 |
Why?
|
| Blood Chemical Analysis | 1 | 2010 | 43 | 0.020 |
Why?
|
| Crosses, Genetic | 1 | 2010 | 60 | 0.020 |
Why?
|
| Umbilical Veins | 1 | 2010 | 54 | 0.020 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2010 | 139 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2012 | 792 | 0.020 |
Why?
|
| Crystallins | 2 | 2001 | 9 | 0.020 |
Why?
|
| Mesenteric Arteries | 1 | 2009 | 29 | 0.020 |
Why?
|
| Apolipoproteins E | 1 | 2010 | 92 | 0.020 |
Why?
|
| Cytoprotection | 1 | 2009 | 39 | 0.020 |
Why?
|
| Cerebral Arteries | 1 | 2009 | 50 | 0.020 |
Why?
|
| Vasodilation | 1 | 2009 | 85 | 0.020 |
Why?
|
| Green Fluorescent Proteins | 1 | 2009 | 200 | 0.020 |
Why?
|
| Quality of Life | 1 | 2017 | 1515 | 0.020 |
Why?
|
| Microfilament Proteins | 1 | 2009 | 102 | 0.020 |
Why?
|
| Cause of Death | 1 | 2010 | 241 | 0.020 |
Why?
|
| Adrenergic beta-2 Receptor Antagonists | 1 | 2008 | 4 | 0.020 |
Why?
|
| Cross Reactions | 1 | 2008 | 57 | 0.020 |
Why?
|
| Gene Transfer Techniques | 1 | 2009 | 173 | 0.020 |
Why?
|
| Erythrocyte Membrane | 2 | 1999 | 20 | 0.020 |
Why?
|
| Erythropoietin | 1 | 2009 | 96 | 0.020 |
Why?
|
| Receptors, Adrenergic, beta-2 | 1 | 2008 | 34 | 0.020 |
Why?
|
| Cell Death | 1 | 2009 | 329 | 0.020 |
Why?
|
| Schiff Bases | 2 | 1999 | 12 | 0.020 |
Why?
|
| Animals, Newborn | 1 | 2009 | 396 | 0.020 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2009 | 223 | 0.020 |
Why?
|
| Cell Adhesion Molecules | 1 | 2009 | 199 | 0.020 |
Why?
|
| Propranolol | 1 | 2008 | 103 | 0.020 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2008 | 69 | 0.020 |
Why?
|
| Phosphoproteins | 1 | 2009 | 202 | 0.020 |
Why?
|
| Protease Inhibitors | 1 | 2008 | 76 | 0.020 |
Why?
|
| Cyclic AMP-Dependent Protein Kinases | 1 | 2008 | 93 | 0.020 |
Why?
|
| RNA, Small Interfering | 1 | 2010 | 434 | 0.020 |
Why?
|
| Carotid Arteries | 1 | 2008 | 110 | 0.020 |
Why?
|
| Epitopes | 1 | 2008 | 146 | 0.020 |
Why?
|
| Population Surveillance | 1 | 2010 | 285 | 0.020 |
Why?
|
| Abbreviated Injury Scale | 1 | 2007 | 12 | 0.020 |
Why?
|
| Cytoplasm | 1 | 2008 | 155 | 0.020 |
Why?
|
| NADPH Oxidases | 1 | 2008 | 80 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2010 | 652 | 0.020 |
Why?
|
| Life Style | 1 | 2010 | 338 | 0.020 |
Why?
|
| Thrombin | 1 | 2008 | 117 | 0.020 |
Why?
|
| Cardiomyopathy, Dilated | 1 | 2008 | 106 | 0.020 |
Why?
|
| Causality | 1 | 2007 | 82 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2009 | 331 | 0.020 |
Why?
|
| Astrocytes | 1 | 2009 | 270 | 0.020 |
Why?
|
| Mass Spectrometry | 1 | 2008 | 284 | 0.020 |
Why?
|
| Age Distribution | 1 | 2007 | 320 | 0.020 |
Why?
|
| Kinetics | 2 | 2001 | 1047 | 0.020 |
Why?
|
| Glyceraldehyde-3-Phosphate Dehydrogenases | 1 | 2006 | 2 | 0.020 |
Why?
|
| Insulin, Regular, Human | 1 | 2006 | 4 | 0.020 |
Why?
|
| Insulin, Long-Acting | 1 | 2006 | 5 | 0.020 |
Why?
|
| Succinic Acid | 1 | 2006 | 9 | 0.020 |
Why?
|
| Serum Albumin, Human | 1 | 2006 | 10 | 0.020 |
Why?
|
| Radiation-Protective Agents | 1 | 2006 | 16 | 0.020 |
Why?
|
| Fumarates | 1 | 2006 | 28 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 2008 | 1447 | 0.020 |
Why?
|
| Anticarcinogenic Agents | 1 | 2006 | 52 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2007 | 714 | 0.020 |
Why?
|
| Muscle Proteins | 1 | 2006 | 94 | 0.020 |
Why?
|
| Fibrinolysis | 1 | 2005 | 55 | 0.020 |
Why?
|
| Antibodies | 1 | 2006 | 241 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2010 | 2077 | 0.020 |
Why?
|
| Models, Statistical | 1 | 2008 | 448 | 0.020 |
Why?
|
| 3' Untranslated Regions | 1 | 2004 | 56 | 0.020 |
Why?
|
| Chromatography, Affinity | 1 | 2004 | 73 | 0.010 |
Why?
|
| Weight Gain | 1 | 2005 | 135 | 0.010 |
Why?
|
| DNA Primers | 1 | 2004 | 302 | 0.010 |
Why?
|
| Length of Stay | 1 | 2007 | 780 | 0.010 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2010 | 767 | 0.010 |
Why?
|
| Lipoproteins, IDL | 1 | 2003 | 8 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2010 | 2007 | 0.010 |
Why?
|
| Cholesterol, VLDL | 1 | 2003 | 17 | 0.010 |
Why?
|
| Sex Distribution | 1 | 2003 | 274 | 0.010 |
Why?
|
| Cyanogen Bromide | 1 | 2001 | 14 | 0.010 |
Why?
|
| Surveys and Questionnaires | 1 | 2010 | 2800 | 0.010 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2000 | 82 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2003 | 1046 | 0.010 |
Why?
|
| src-Family Kinases | 1 | 2000 | 91 | 0.010 |
Why?
|
| Amines | 1 | 1999 | 98 | 0.010 |
Why?
|
| In Vitro Techniques | 1 | 1999 | 765 | 0.010 |
Why?
|
| Immune Sera | 1 | 1997 | 30 | 0.010 |
Why?
|
| Membrane Lipids | 1 | 1997 | 31 | 0.010 |
Why?
|
| Phosphatidylethanolamines | 1 | 1997 | 20 | 0.010 |
Why?
|
| Hydrolysis | 1 | 1997 | 144 | 0.010 |
Why?
|
| Drug Stability | 1 | 1997 | 71 | 0.010 |
Why?
|
| Ribonucleases | 1 | 1997 | 25 | 0.010 |
Why?
|
| Glyoxal | 1 | 1996 | 2 | 0.010 |
Why?
|
| Amino Acids | 1 | 1997 | 131 | 0.010 |
Why?
|
| Arachidonic Acid | 1 | 1996 | 86 | 0.010 |
Why?
|
| Models, Chemical | 1 | 1997 | 155 | 0.010 |
Why?
|
| Pentetic Acid | 1 | 1994 | 18 | 0.010 |
Why?
|
| Chelating Agents | 1 | 1994 | 47 | 0.010 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 1994 | 272 | 0.010 |
Why?
|
| Tendons | 1 | 1994 | 45 | 0.010 |
Why?
|
| Cross-Linking Reagents | 1 | 1994 | 80 | 0.010 |
Why?
|
| Spectrophotometry, Ultraviolet | 1 | 1993 | 79 | 0.010 |
Why?
|
| Reference Values | 1 | 1994 | 579 | 0.010 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 1994 | 381 | 0.010 |
Why?
|
| Lens, Crystalline | 1 | 1991 | 39 | 0.010 |
Why?
|